The global adrenocortical carcinoma drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). One of the key factors that are primarily driving the growth of the market includes the comparative advantages of novel drugs over chemotherapeutics. Chemotherapeutics such as mitotane can cause major side effects including peripheral neuropathy and seizures. This is expected to increase the use of novel drugs, which show long-term efficacy and potential benefits in patients.

Another key factor driving the market growth includes the rising advancements in imaging techniques for detecting tumors and adrenal lesions. Various imaging techniques with enhanced diagnostic accuracy as a non-invasive approach have been developed for adrenocortical carcinoma. For instance, the multiphase computed tomography technique is one of the latest imaging techniques which can calculate both the absolute percentage and the relative percentage washout, which helps in identifying both benign and malignant lesions of the adrenal gland. Thus, advances in imaging techniques for adrenal tumors is anticipated to fuel the growth of the global adrenocortical carcinoma drugs market during the forecast period.

Some key players operating in the market include Bristol-Myers Squibb Co.,  Merck & Co., Inc., and Laboratoire HRA-Pharma SAS, among others. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in November 2021, Merck announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line treatment of patients with radically unresectable, advanced or recurrent esophageal carcinoma in combination with chemotherapy (5-fluorouracil [5-FU] plus cisplatin) based on data from the Phase 3 KEYNOTE-590 trial.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape:  Bristol-Myers Squibb Co., Merck & Co., Inc., and Laboratoire HRA-Pharma SAS, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Adrenocortical Carcinoma Drugs Market by Segment

By Type 

• Chemotherapy

• Targeted therapy

By Application 

• Hospital

• Research Institute

• Clinic

• Other

Global Adrenocortical Carcinoma Drugs Market by Region